Related Experiment Video
Updated: May 26, 2026
10:28
Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
Published on: July 24, 2019
Pharmacogenomics in neurology: current state and future steps.
Andrew Chan1, Munir Pirmohamed, Manuel Comabella
1Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Germany. andrew.chan@rub.de
Annals of Neurology
|December 14, 2011
Summary
Pharmacogenomics uses genetic variations to tailor neurological treatments, optimizing drug efficacy and reducing side effects. Further research with larger, standardized studies is crucial for clinical application in neurology.
Area of Science:
- Neurology
- Pharmacogenomics
- Genetics
Background:
- Optimizing neurological therapies requires patient stratification to enhance efficacy and minimize toxicity.
- Pharmacogenomics investigates the link between human genome variations and diverse drug responses.
- Current clinical applications of pharmacogenomics in neurology are limited due to inconsistent study results.
Purpose of the Study:
- To review advances and limitations of pharmacogenomics in neurological treatment strategies.
- To highlight the need for improved biomarkers for patient selection in neurological therapies.
- To discuss future directions for pharmacogenomic research in various neurological conditions.
Main Methods:
- Review of recent literature on pharmacogenomics in neuroimmunology, neurodegenerative diseases, ischemic stroke, epilepsy, and primary headaches.
- Analysis of candidate gene approaches (pharmacokinetic and pharmacodynamic pathways).
- Discussion of limitations including small sample sizes, inadequate phenotyping, and genotyping.
Main Results:
- Few genetic variants are currently incorporated into clinical algorithms for neurological treatments.
- Contradictory results in existing studies hinder clinical translation.
- Significant need exists for robust biomarkers to guide treatment decisions.
Conclusions:
- Pharmacogenomics holds promise for personalized neurological therapies.
- Standardized phenotyping, larger multicenter studies, and advanced technologies (genome-wide, next-generation sequencing, systems biology) are essential.
- Progress in pharmacogenomics will improve benefit-harm balance, cost-efficiency, and drug discovery in neurology.
Related Concept Videos
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...